|
| 37523146 | High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer. | Cancer Res | 2023 |
| 36346110 | Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. | Int J Cancer | 2023 |
| 37001527 | Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. | Cancer Cell | 2023 |
| 36867694 | Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma. | Sci Adv | 2023 |
| 34471258 | Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. | Br J Cancer | 2022 |
| 35567751 | Quantification of vincristine and tariquidar by liquid chromatography-tandem mass spectrometry in mouse whole blood using volumetric absorptive microsampling for pharmacokinetic applications. | Journal of Separation Science | 2022 |
| 34297633 | "We Have All This Knowledge to Give, So Use Us as a Resource": Partnering with Adolescent and Young Adult Cancer Survivors to Determine Consumer-Led Research Priorities. | J Adolesc Young Adult Oncol | 2022 |
| 35080351 | GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators. | FEBS J | 2022 |
| 34998954 | miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma. | Mol Ther | 2022 |
| 34807782 | Methodological advances in the discovery of novel neuroblastoma therapeutics. | Expert Opin Drug Discov | 2022 |
| 34826366 | A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma. | Curr Protoc | 2021 |
| 33994371 | Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. | Clin Cancer Res | 2021 |
| 33712556 | Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors. | Cell Death Dis | 2021 |
| 33310889 | Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. | Clin Cancer Res | 2021 |
| 34983733 | Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition. | Drug Resist Updat | 2021 |
| 32684628 | CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma. | Br J Cancer | 2020 |
| 32259094 | Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma. | ACS Pharmacology and Translational Science | 2020 |
| 32123312 | Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition. | Oncogene | 2020 |
| 31989509 | Mouse models of high-risk neuroblastoma. | Cancer and Metastasis Reviews | 2020 |
| 31919402 | Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. | Br J Cancer | 2020 |
| 32086952 | Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma. | Int J Cancer | 2020 |
| 31862449 | CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth. | Biochem Pharmacol | 2020 |
| 32651259 | Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression. | Cancer Res | 2020 |
| 30700572 | Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. | Sci Transl Med | 2019 |
| 31302132 | MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. | Biochem Pharmacol | 2019 |
| 29632319 | Too many targets, not enough patients: rethinking neuroblastoma clinical trials. | Nat Rev Cancer | 2018 |
| 27923830 | A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. | Cancer Res | 2017 |
| 28735070 | Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo. | Eur J Cancer | 2017 |
| 26996379 | Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. | Mol Oncol | 2016 |
| 26848616 | The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression. | Oncotarget | 2016 |
| 27197171 | MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin. | Cancer Res | 2016 |
| 27180306 | ABC transporters as mediators of drug resistance and contributors to cancer cell biology. | Drug Resist Updat | 2016 |
| 25860940 | MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. | Oncotarget | 2015 |
| 25462817 | Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen. | Biochemical Pharmacology | 2015 |
| 24973542 | High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). | Biochem Pharmacol | 2014 |
| 23396365 | RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model. | Oncogene | 2014 |
| 22202125 | N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma. | Cancer Res | 2012 |
| 21799180 | ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. | J Natl Cancer Inst | 2011 |
| 20075923 | ABC transporters in cancer: more than just drug efflux pumps. | Nat Rev Cancer | 2010 |
| 21203485 | Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. | PLoS Pathogens | 2010 |
| 19603790 | Discovery of inhibitors of lupin diadenosine 5',5'''-P(1),P(4)-tetraphosphate hydrolase by virtual screening. | Biochemistry | 2009 |
| 18196961 | Controlling the cell death mediators Bax and Bak: puzzles and conundrums. | Cell Cycle | 2008 |
| 18981409 | Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. | Proceedings of the National Academy of Sciences of the United States of America | 2008 |
| 17382885 | Programmed anuclear cell death delimits platelet life span. | Cell | 2007 |
| 17289999 | Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. | Science | 2007 |
| 16763613 | BH3-only proteins: orchestrating cell death. | Cell Death and Differentiation | 2006 |
| 16869785 | Subversion of the Bcl-2 life/death switch in cancer development and therapy. | Cold Spring Harbor Symposia on Quantitative Biology | 2005 |
| 15772762 | 1H, 13C, and 15N resonance assignments of the 17 kDa Ap4A hydrolase from Homo sapiens in the presence and absence of ATP. | Journal of Biomolecular NMR | 2005 |
| 15694340 | Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. | Molecular Cell | 2005 |
| 15901672 | Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. | Genes and Development | 2005 |